This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
EnVVeno Medical Corporation Announces Additional Topline Efficacy Data from the VenoValve U.S. Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024 CI
EnVVeno Medical Corporation Appoints Andrew Cormack as Its Chief Commercial Officer CI
EnVVeno Announces Positive Topline Efficacy Data for VenoValve US Pivotal Trial MT
EnVVeno Medical Corporation Announces the Presentation of Positive Topline Efficacy Data Showing Significant Clinical Improvement from the Savve U.S. Pivotal Trial for the Venovalve CI
EnVVeno Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
EnVVeno Medical Corporation Presents Positive Preliminary Device Related Material Adverse Event Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium CI
EnVVeno Medical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
EnVVeno Achieves Full Enrollment for VenoValve Trial; to Conduct Preclinical Trial of Another Venous Valve Product MT
EnVVeno Medical Corporation Achieves Full Enrollment for VenoValve U.S. Pivotal Trial CI
EnVVeno Medical Corporation announced that it expects to receive $27.997135 million in funding CI
EnVVeno Medical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Envveno Medical Corporation Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study CI
EnVVeno Medical Corporation(NasdaqCM:NVNO) added to Russell 3000E Growth Index CI
EnVVeno Medical Corporation(NasdaqCM:NVNO) added to Russell Microcap Growth Index CI
EnVVeno Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
EnVVeno Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Envveno Medical Promotes Hamed Alavi to Senior Vice President and Chief Technology Officer CI
Envveno Medical Corporation Presents Positive Long-Term, Three-Year Observational Data from A Cohort of Patients That Participated in the Previously Concluded Venovalve First-In-Human Clinical Tria CI
EnVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study CI
EnVVeno Medical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
EnVVeno Medical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
EnVVeno Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
EnVVeno Medical Secures US Patent for Manufacturing Method Related to VenoValve MT
EnVVeno Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2021 CI
EnVVeno Medical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Chart enVVeno Medical Corporation
More charts
enVVeno Medical Corporation is a late-stage clinical med-tech company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system of the leg. The Company's lead product, VenoValve, which is a porcine based replacement venous valve developed to surgically implanted in the deep venous system of the leg to treat severe CVI. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter based replacement venous valve.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
5.5 USD
Average target price
20.4 USD
Spread / Average Target
+270.91%
Consensus
  1. Stock Market
  2. Equities
  3. NVNO Stock
  4. News enVVeno Medical Corporation
  5. Hancock Jaffe Laboratories : Will Change Name to enVVeno Medical in October